stockportfolio.pro logostockportfolio.pro
Stocks Screener Start 7-day free trial
Stocks / UTHR / Revenue

United Therapeutics Corporation Revenue 2008–2025

United Therapeutics Corporation (UTHR) annual revenue by fiscal year, computed from SEC filings. Compound growth +15.3%/yr over 17 years.

Fiscal yearRevenueChange (YoY)
FY 2025$3.18B+10.6%
FY 2024$2.88B+23.6%
FY 2023$2.33B+20.2%
FY 2022$1.94B+14.9%
FY 2021$1.69B+13.6%
FY 2020$1.48B+2.4%
FY 2019$1.45B-11.0%
FY 2018$1.63B-5.7%
FY 2017$1.73B+7.9%
FY 2016$1.60B+9.1%
FY 2015$1.47B+13.8%
FY 2014$1.29B+15.4%
FY 2013$1.12B+21.9%
FY 2012$916.08M+23.3%
FY 2011$743.18M+25.3%
FY 2010$592.90M+65.2%
FY 2009$358.88M+27.5%
FY 2008$281.50M

Source: United Therapeutics Corporation SEC filings — income statement (10-K). Refreshed nightly.

See the full picture for United Therapeutics Corporation

Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.

Open the interactive view — free

United Therapeutics Corporation — frequently asked questions

What is United Therapeutics Corporation's revenue?

United Therapeutics Corporation (UTHR) reported revenue of $3.18B for fiscal year 2025, per its SEC filings.

How has United Therapeutics Corporation's revenue changed over time?

Between fiscal 2008 and 2025, UTHR's revenue grew at roughly 15.3% per year (compound annual rate), from $281.50M to $3.18B.

Where does this data come from?

Figures are computed from United Therapeutics Corporation's official SEC filings (income statement (10-K)), refreshed nightly. Not investment advice.

More UTHR financial history

Full UTHR fundamentals page → · All 1,500+ companies →